If you are on social media, a member of the Society or simply stay close to community news, you will have likely seen our recent video campaign, #letstalkvitiligo. Released on the 19th March, the campaign was aligned with the release of a UK wide survey of over 700 people that revealed the impact vitiligo can have on a person’s life. Since its release date, the campaign has done incredibly well. The video itself was a collaboration between trustees and Society volunteers who spoke candidly about how vitiligo has made them feel, some of the challenges they’ve faced and society perceptio ..read more

The Scottish Medicines Consortium (SMC) has announced that it is now considering Ruxolitinib (Opzelura) or treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. What is Opzelura? Developed by pharmaceutical company Incyte Biosciences, Opzelura is a medicine developed for treating non-segmental vitiligo. It is a topical selective Janus kinase (JAK) inhibitor cream that affects your immune system, reducing inflammation and encouraging the regeneration of melanocytes to produce pigment over time. What is the SMC? The Scottish Medicines Co ..read more

The National Institute for Health and Care Excellence (NICE) are currently appraising the clinical and cost effectiveness of Ruxolitinib within its marketing authorisation for treating non-segmental vitiligo in people 12 years and over. The importance of this is that, if approved, it could make Ruxolitinib available on the NHS. 11th January 2024 Technology Appraisal Committee Meeting The appraisal was discussed by the technology appraisal committee on 11th January 2024. The appraisal committee reached a conclusion not to recommend ruxolitinib, within its marketing authorisation, for tr ..read more

Our charity recently commissioned ground-breaking research to understand the physical, psychological and social implications of vitiligo. This major study, conducted by an independent research organisation, included responses from over 700 people and was the largest ever survey of people living with vitiligo in the UK.  The results reveal significant findings which highlight the pressing need for better support for people with the condition. Using this data, we have now launched a PR campaign to publicise the findings with national and regional media. By doing this, we seek to raise a ..read more

Sorry, but you do not have permission to view this content ..read more

Sorry, but you do not have permission to view this content ..read more

Sorry, but you do not have permission to view this content ..read more

CLINUVEL, a pharmaceutical group specialised in creating commercial products to treat chronic medical conditions, are looking to conduct an investigational therapy using afamelanotide to evaluate its usage as a treatment for vitiligo patients with darker skin types. What is this study about? The purpose of this study is to evaluate if afamelanotide combined with Narrow-Band Ultraviolet B (NB-UVB) can improve repigmentation and for how long the pigmentation is maintained after the treatment is complete. Additionally, the study will investigate the safety of this treatment for patients with v ..read more

Sorry, but you do not have permission to view this content ..read more

Whilst it is possible to live with vitiligo and thrive, there can be no doubt that for many people being diagnosed with vitiligo can have a considerable impact on their life, and their confidence to carry out everyday activities. It’s important that people living with vitiligo feel empowered to talk to their employer if they feel their vitiligo is impacting their career, and its equally important tn encourage employers to take the time to learn about how vitiligo may be affecting an employee. Together you can work to identify ways in which to create a supportive workplace environment for so ..read more